GeneHealth - Your precision medicine

Brucella Melitensis Brucellosis

Disease Details

Family Health Simplified

Buy Membership

Description: Brucella melitensis brucellosis is a zoonotic bacterial infection transmitted from animals, particularly goats and sheep, to humans, causing fever, sweats, and joint pain.
Type: Brucella melitensis brucellosis is a bacterial infection. It is primarily transmitted through direct contact with infected animals or consumption of contaminated animal products, rather than through genetic transmission.
Signs And Symptoms: Brucella melitensis causes brucellosis, also known as Malta fever or Mediterranean fever. The signs and symptoms of brucellosis can vary widely but commonly include:

- Fever (often intermittent or irregular)
- Sweats, especially at night
- Fatigue and malaise
- Joint and muscle pain
- Headache
- Loss of appetite and weight loss

In more severe cases, brucellosis can lead to complications affecting various organs, such as the liver, spleen, and heart. Chronic infection can cause recurrent fevers, joint infections, and neurological symptoms.
Prognosis: Brucella melitensis brucellosis has a generally good prognosis with appropriate treatment, but it can be challenging due to possible complications and relapses. The prognosis depends on timely diagnosis and effective antibiotic treatment. Without treatment, the disease can become chronic, leading to more severe health issues such as endocarditis, arthritis, and neurological complications.
Onset: The onset of brucellosis caused by Brucella melitensis typically occurs within 1 to 3 weeks after exposure but can range from a few days to several months.
Prevalence: The prevalence of Brucella melitensis, which causes brucellosis, varies geographically. It is more commonly found in Mediterranean countries, parts of Asia, Africa, Latin America, and the Middle East. Prevalence can be higher in rural areas where livestock farming is prevalent, as the bacteria primarily infect sheep and goats. Improved veterinary control and public health measures have reduced its incidence in some regions, but it remains a significant concern in areas with less stringent animal health regulations.
Epidemiology: Brucella melitensis brucellosis primarily affects sheep and goats but can also infect humans. It is common in regions like the Mediterranean, Middle East, Central Asia, and parts of Latin America and sub-Saharan Africa. Transmission to humans typically occurs through direct contact with infected animals or consumption of contaminated animal products, such as unpasteurized milk. The disease is characterized by febrile illness and can lead to chronic conditions if untreated.
Intractability: Brucella melitensis brucellosis is not considered intractable, as it can be treated effectively with antibiotics. However, it requires timely diagnosis and an appropriate combination of antibiotics, typically doxycycline and rifampin, for a prolonged period (usually 6 weeks). Delayed treatment or inadequate therapy can lead to complications and chronic infection, which might be more challenging to manage.
Disease Severity: Brucella melitensis brucellosis is a bacterial infection caused by Brucella melitensis, primarily affecting sheep and goats, but can also infect humans. In humans, it is considered a severe disease due to its potential to cause prolonged illness with a variety of symptoms including fever, sweats, malaise, anorexia, headache, pain in muscles, joint, and/or back, and fatigue. Chronic infection can lead to more serious complications like arthritis, endocarditis, or involvement of the liver or spleen. Prompt and adequate treatment is important to prevent severe complications.
Healthcare Professionals: Disease Ontology ID - DOID:14456
Pathophysiology: Brucella melitensis brucellosis is an infectious disease caused by the bacterium Brucella melitensis. Here is the pathophysiology:

1. **Entry and Transmission:** Brucella melitensis typically infects humans through direct contact with infected animals or consumption of contaminated animal products, such as unpasteurized milk and cheese. The bacterium can also enter through skin abrasions, inhalation, or mucosal surfaces.

2. **Initial Infection:** Upon entry, Brucella melitensis is phagocytosed by macrophages and other immune cells. Instead of being destroyed, it adapts to survive and replicate within these cells by inhibiting phagosome-lysosome fusion and oxidative burst, which are primary defense mechanisms of phagocytes.

3. **Intracellular Survival:** The bacterium localizes in the endoplasmic reticulum-derived compartment within host cells, where it is shielded from the immune response and able to acquire nutrients for replication. This intracellular niche allows Brucella melitensis to persist and disseminate within the host.

4. **Immune Evasion:** Brucella melitensis has mechanisms to modulate the host immune response. It can downregulate the production of pro-inflammatory cytokines and delay the apoptosis of infected cells, helping it evade immune detection and destruction.

5. **Dissemination and Granuloma Formation:** The bacteria can spread to various organs including the liver, spleen, bone marrow, and lymph nodes through the bloodstream. The immune response eventually leads to the formation of granulomas, which are collections of immune cells attempting to wall off the bacteria. These granulomas can cause organomegaly and dysfunction due to the persistent infection and immune response.

6. **Chronic Infection:** If untreated or inadequately treated, Brucella melitensis can cause chronic infection, characterized by intermittent fever, malaise, and other systemic symptoms. The bacteria can persist in tissues for long periods, leading to relapsing fever and other complications, such as arthritis, endocarditis, and hepatosplenomegaly.

This progression from acute infection to chronic state underscores the pathogenicity and clinical challenges associated with Brucella melitensis brucellosis.
Carrier Status: Carrier status for brucella melitensis brucellosis is not applicable in the traditional sense. Unlike some other infections where asymptomatic carrier states exist, brucellosis typically presents with symptoms if the bacteria are present in the body. However, chronic forms of the disease can occur, where symptoms are intermittent and the bacteria can persist in the body even after treatment.
Mechanism: Brucella melitensis, the causative agent of brucellosis, primarily infects livestock but can also infect humans through direct contact with infected animals or consumption of contaminated animal products. Here are the key aspects of its mechanism and molecular mechanisms:

### Mechanism

1. **Entry and Transmission**: B. melitensis can enter the human body through mucous membranes, skin abrasions, or inhalation. The bacteria can be transmitted via direct contact with infected animals, consumption of unpasteurized dairy products, or inhalation of aerosols.

2. **Invasion and Intracellular Survival**: Once inside the body, B. melitensis can invade and replicate within the host's macrophages, a type of immune cell. The bacteria use a specialized secretion system (Type IV secretion system, T4SS) to inject effector proteins into host cells, facilitating their entry and survival within phagosomes.

### Molecular Mechanisms

1. **Type IV Secretion System (T4SS)**: The T4SS, encoded by the virB operon, is critical for the intracellular survival and replication of B. melitensis. This system helps the bacterium evade the host's immune response by manipulating phagosome-lysosome fusion, allowing it to create a modified compartment where it can survive and replicate.

2. **Lipopolysaccharides (LPS)**: The outer membrane of B. melitensis contains smooth lipopolysaccharides that provide resistance to the host's antimicrobial peptides and complement system. This LPS plays a role in immune evasion.

3. **Stress Response Proteins**: B. melitensis expresses several stress response proteins, including DnaK, GroEL, and HtrA, which aid in survival under the hostile conditions within the host macrophages, such as oxidative and nitrosative stress.

4. **Virulence Factors**: B. melitensis produces various virulence factors like BvrR/BvrS two-component regulatory system (which controls the expression of outer membrane proteins), and flagella that, although not used for motility inside the host, play parts in initial host interactions.

Understanding these mechanisms is essential for developing effective treatments and preventive measures against brucellosis.
Treatment: Treatment for Brucella melitensis brucellosis typically involves a combination of antibiotics to ensure efficacy and prevent relapse. The commonly recommended regimen includes doxycycline (100 mg twice daily) combined with rifampin (600-900 mg daily) for a duration of at least 6 weeks. In some cases, gentamicin or streptomycin may be added for the initial 1-2 weeks of treatment to enhance effectiveness. It's crucial to follow the complete course of therapy to avoid chronic infection or complications. Consult your healthcare provider for a diagnosis and treatment plan tailored to individual needs.
Compassionate Use Treatment: For Brucella melitensis brucellosis, compassionate use or off-label treatments are typically those considered when standard therapies fail or are not tolerated. Compassionate use involves access to investigational drugs still under study but not yet approved for general use. Experimental treatments may include newer antibiotics or combination therapies not standardly used. Clinical trials occasionally explore novel drugs or regimens; for specific treatment options and access, consultation with an infectious disease specialist and adherence to regulatory pathways is crucial.
Lifestyle Recommendations: For individuals with Brucella melitensis brucellosis, the following lifestyle recommendations can help manage the condition and prevent further complications:

1. **Medication Adherence**: Follow the prescribed antibiotic regimen strictly to ensure full eradication of the bacteria.
2. **Rest and Hydration**: Ensure adequate rest and stay well-hydrated to help your body recover.
3. **Avoid Raw Dairy Products**: Do not consume unpasteurized milk or dairy products, as they can be sources of infection.
4. **Safe Animal Handling**: Use protective gear when handling animals, particularly livestock, to avoid direct contact with infectious fluids.
5. **Regular Medical Check-ups**: Maintain regular follow-up appointments with your healthcare provider to monitor the disease and progress of treatment.
6. **Occupational Safety**: If you work in a high-risk environment (e.g., farming or veterinary services), implement strict hygiene and biosecurity measures.

Adopting these lifestyle practices can support better management of brucellosis and reduce the risk of transmission.
Medication: The primary medications used to treat Brucella melitensis brucellosis typically include a combination of antibiotics. The standard regimen often involves doxycycline and rifampin taken together for a duration of at least six weeks. In some cases, streptomycin or gentamicin may also be used in combination with doxycycline, especially for more severe or complicated cases. Always follow the guidance of a healthcare professional for diagnosis and treatment.
Repurposable Drugs: For Brucella melitensis brucellosis, repurposable drugs include doxycycline and rifampin. These antibiotics are commonly used in combination to effectively treat the infection.
Metabolites: Brucella melitensis brucellosis, commonly known as brucellosis, is an infectious disease caused by the bacterium Brucella melitensis. This bacterium primarily affects livestock such as goats and sheep but can also infect humans. Metabolites associated with Brucella melitensis include:

1. **Erythritol**: A sugar alcohol found in high concentrations in the reproductive tissues of animals, promoting the growth of Brucella organisms.
2. **Glucose-6-phosphate**: Utilized by the bacteria for energy production.
3. **ATP (Adenosine Triphosphate)**: Produced through bacterial metabolism and necessary for various cellular processes.

Due to the focus on Brucella melitensis brucellosis, no nan in the given context. If you need further details or specific types of metabolites, please let me know.
Nutraceuticals: Nutraceuticals are not currently a primary approach for managing Brucella melitensis brucellosis. This bacterial infection typically requires antibiotic treatment for effective management. The most common antibiotics used are doxycycline and rifampin, administered together for a period of at least six weeks. Any consideration of nutraceuticals should be discussed with a healthcare professional to ensure they do not interfere with standard treatment protocols.
Peptides: Brucella melitensis brucellosis is an infectious disease caused by the bacterium Brucella melitensis. It affects various animals, especially goats and sheep, and can also infect humans. Peptides related to this disease often refer to those involved in immune response or vaccine development. Nanoparticles have been explored for targeted drug delivery and vaccine carriers to enhance immune responses against the bacterium.